Abstract
Oncolytic virotherapy with Parvovirus H-1 (H-1PV) represents a new therapeutic approach currently investigated in a phase I/IIa clinical trial recruiting adult patients with recurrent glioblastoma. For pediatric high-grade glioma patients there is also an urgent need of new therapeutic options. Here we analyzed, whether H-1PV is able to infect, to transduce and to selectively eliminate cell culture models of diffuse intrinsic pons glioma (DIPG) and pediatric glioblastoma in vitro.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
